Compounds such as BEZ23518 (Table 1), which inhibit both PI 3-kinase and mTOR (which are related enzymes), may be of utility in cancer therapy by virtue of their ability both to inhibit two oncogenic pathways and to prevent the consequences of mTOR inhibitor-induced activation of PI 3-kinase/Akt signalling. Here, MTOR is linked to cancer.